Brief: Sernova Biotherapeutics Provides Positive Interim Data From Ongoing Phase 1/2 Clinical Trial Of Cell Pouch Bio-Hybrid Organ In Patients Living With Type 1 Diabetes
14/05/2025 13:24
May 14 (Reuters) - Sernova Biotherapeutics Inc SVA.TO: SERNOVA BIOTHERAPEUTICS PROVIDES POSITIVE INTERIM DATA FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF CELL POUCH BIO-HYBRID ORGAN IN PATIENTS LIVING WITH TYPE 1 DIABETES SERNOVA BIOTHERAPEUTICS INC - CLINICAL STUDY ON TRACK TO MEET ITS PRIMARY AND SECONDARY ENDPOINTS SERNOVA BIOTHERAPEUTICS INC - ALL PATIENTS REACHED OR MAINTAINED ADA RECOMMENDED HBA1C OF <7.0% Source text: ID:nGNX6THm5n Further company coverage: SVA.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sernova Biotherapeutics
See all newsBrief: Seraxis And Sernova Announce Appointment Of Former FDA Medical Officer Dr. Patricia Beaston As Chief Medical Officer Of Seraxis And Post Merger Betanova Biotherapeutics
Brief: Sernova Appoints Jonathan Rigby As Interim Chair
Brief: Sernova Biotherapeutics Provides Positive Interim Data From Ongoing Phase 1/2 Clinical Trial Of Cell Pouch Bio-Hybrid Organ In Patients Living With Type 1 Diabetes
Brief: Sernova Biotherapeutics Secures $4 Million Loan To Further Advance Its Clinical Development Plans
Brief: Sernova Biotherapeutics Inc Study Is On Track To Meet Key Clinical Trial Endpoints